Full COLD-PCR Protocol for Noninvasive Prenatal Diagnosis of Genetic Diseases

To the Editor:
After the discovery of fetal DNA in maternal plasma, investigators reported different strategies for the noninvasive prenatal diagnosis of genetic diseases (1 ) . Despite the advances in improving the analytical sensitivity of methods, distinguishing between fetal and maternal sequences remains very challenging, and the field of noninvasive prenatal diagnosis of genetic diseases has yet to attain a routine application in clinical diagnostics. An innovative strategy that has been reported is based on COLD-PCR (coamplification at a lower denaturation temperature PCR), 1 which exploits melting temperature (T m ) differences between variant or mismatched sequences and wild-type sequences. This approach uses a critical denaturation temperature (T c ) lower than the T m to selectively amplify minority mutated alleles (2 ).
We have developed assays for the identification of fetal paternally inherited mutations in maternal plasma. These assays use full COLD-PCR for the detection of IVSI.110 (GϾA) and Cd39 (CϾT) HBB (globin, beta) gene mutations that cause ␤-thalassemia.
Full COLD-PCR is based on the generation of heteroduplexes between mutant and wild-type sequences. These heteroduplexes melt at lower temperatures than the wild-type homoduplexes. They are selectively denatured at the T c and then subsequently amplified. Given that both the fetal and maternal DNA content in maternal plasma has been demonstrated to vary from pregnancy to pregnancy (3 ), we used a range of T c values and several replicates of the same sample to develop a protocol that was specific for the identification of each mutation. To simplify the T c evaluation, we amplified plasma DNA from wild-type controls with a conventional PCR protocol and several replicates of the same sample and varied the denaturation temperature. The lowest denaturation temperature that still allowed amplification of wild-type samples (81.9°C for IVSI.110, 83.8°C for Cd39) was chosen as the upper limit of a T c interval, which spanned 1°C. We scaled the denaturation temperatures for 8 replicates of the maternal plasma sample down by increments of 0.1°C-0.2°C, beginning with the upper T c value identified. The use of a range of potential T c values with several replicates instead of a single T c ensured that at least 1 replicate exhibited differential denaturation of mutant and wild-type alleles, thereby allowing robust PCR amplification.
The study was approved by the local ethics review boards. After obtaining written informed consent from couples in which the parents carried different mutations, we collected 6 mL of maternal blood before chorionic villus sampling. DNA was extracted from 500 L of plasma (4 ) and eluted in a 60-L volume. COLD-PCR was performed in a 25-L final volume containing 5 L of eluted DNA, 200 mol/L of each deoxynucleoside triphosphate, 10 mmol/L Tris-HCl (pH 8.3), 50 mmol/L KCl, 1.5 mmol/L MgCl 2 , 1.5 U of FastStart Taq DNA polymerase (Roche Applied Science), and 10 pmol of each primer. Cycling conditions were as follows: 95°C for 4 min; 25 cycles of 95°C for 15 s, 54°C for 30 s, and 72°C for 1 min; 72°C for 10 min; 95°C for 4 min; 35 cycles of 95°C for 15 s, 70°C for 8 min (to generate heteroduplexes), specific T c temperature for 3 s, and 72°C for 1 min; 72°C for 7 min. For IVSI.110, the T c interval was 81.9°C-80.9°C; for Cd39, the T c interval was 83.8°C-82.8°C. The amplification primers for IVSI.110 were 5Ј-TAAGGAGAC CAATAGAAACT-3Ј (forward) and 5Ј-GTAGACCACCAGCAGC-3Ј (reverse); the amplicon size was 119 bp. The primers for Cd39 were 5Ј-GTCTATTTTCCCACCCTT-3Ј (forward) and 5Ј-AGCACTTTCTTG CCATGA-3Ј (reverse); the amplicon size was 134 bp. After COLD-PCR, samples were sequenced directly with the 3730 DNA Analyzer (Applied Biosystems). We performed 35 diagnoses-for 21 cases in which the father carried the Cd39 mutation (the fetus inherited the paternal mutation in 10 of these cases) and for 14 cases in which the father carried the IVSI.110 mutation (the fetus inherited the paternal mutation in 12 of these cases). In all cases, the fetal paternal mutated allele was not detectable by conventional PCR, whereas the mutation was evident after COLD-PCR. Fig. 1 shows examples of samples lacking the paternally inherited mutated allele, as well as the lowest and highest enrichments of fetal paternally inherited mutated alleles for both mutations. The results obtained with COLD-PCR were in complete concordance with those obtained for fetal DNA extracted from chorionic villi (Fig. 1) . Du et al. described the use of fetal circulating DNA and fast COLD-PCR to detect congenital paternal abnormalities in a single individual (5 ). Fast COLD-PCR cannot detect all mutations, however. To our knowledge, the present report is the first to indicate the feasibility of using full COLD-PCR for prenatal diagnosis in a comprehensive study.
We have provided evidence that COLD-PCR enables straightforward and reliable identification of inherited mutated alleles without the need for sophisticated and costly equipment. The method might be extended to noninvasive prenatal diagnosis of genetic diseases, and it has the potential to be easily transferable to clinical diagnostic laboratories. 
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Fig. 1. Sequence analysis of maternal plasma samples.
Indicated are lowest (1) and highest (2) enrichment of the fetal mutated allele after COLD-PCR and sequencing; results for fetal DNA extracted from chorionic villi (3); fetal mutated allele undetectable with conventional PCR and sequencing (4); and no visible peak of mutated allele when the fetus inherited the paternal wild-type allele (5). The prevalence and incidence of metabolic bone disease are rising as the population ages (1 ). In conjunction with imaging and clinical history, biochemical bone markers have become increasingly important in diagnosis and for monitoring bone disease (2, 3 ).
Little evidence is available regarding preanalytical influences on short-term stability of bone markers. We have evaluated the effects of sample type, processing, and storage procedures on the stability of biochemical markers of bone turnover [C-terminal telopeptide of type 1 collagen (␤-CTX), N-terminal propeptide of procollagen type 1 (P1NP), osteocalcin (OC), bone-specific alkaline phosphatase (bone ALP), and parathyroid hormone (PTH)].
After obtaining informed consent, we collected venous blood samples from 18 patients with metabolic bone disease into lithium heparincontaining, EDTA-containing, and serum Sarstedt blood-collection systems.
We investigated the use of 3 sample-processing protocols (6 patients each): (a) delayed separation from cells (samples stored at room temperature for 1, 2, 4, 8, 24, or 48 h after venesection before separation); (b) immediate separation and storage at room temperature (plasma and serum aliquots left at room temperature for 2 h, 4 h, 8 h, 24 h, 48 h, or 7 days); and (c) immediate separation and storage at 2°C-8°C (plasma and serum aliquots stored at 2°C-8°C for 24 h, 48 h, 7 days, 14 days, or 28 days).
All samples were then stored at Ϫ70°C until analysis of each batch. Baseline samples for each sample type (produced by immediate separation and storage of plasma or serum aliquots at Ϫ70°C) were analyzed for all patients. We measured ␤-CTX, P1NP, OC, and PTH on the Modular Analytics E 170/Elecsys® platform (Roche). In addition, we used the Metra Biosystems enzymatic immunoassay to measure bone ALP (in duplicate, serum samples only) in 3 patients from each sample-processing protocol. The assays were assessed for intraassay imprecision by duplicate analysis of each sample for each container type, and interassay imprecision was assessed with QC material. For all assays, mean CVs were Ͻ10%.
After analysis, we used 1-way ANOVA with Bonferroni-corrected post hoc t-tests to compare analyte concentrations at each time point with the baseline concentration ( Table 1) . Mean values were considered significantly different at P values Ͻ0.05.
The stability of each analyte was evaluated according to the criteria of the 2002 WHO guidelines (4, 5 ) and was defined as the amount of time the change in concentration remained less than half of the total error of the sum of the biological and analytical variation. The calculated value was Ͻ5.4%
